Aeronide 200

Budesonide

Maintenance treatment of bronchial asthma as prophylactic therapy.

Adult & childn >12 yr Recommended dose: 200-1,600 mcg daily in 2-4 divided doses. Less severe cases 200-800 mcg daily. Patients w/ mild to moderate asthma who have not previously received inhaled glucocorticosteroids 200-400 mcg daily. Patients w/ mild to moderate asthma already controlled on inhaled steroids eg, budesonide or beclomethasone dipropionate 800 mcg bid. More severe cases 800-1,600 mcg daily. Administration bid (morning & evening) is sufficient. Patients in severe asthma & during exacerbations Divided daily dose into 3-4 doses/day. Mild asthmatics Requiring up to 400 mcg daily (in the morning or evening). Maintenance dose: Individualized dose. Recommended dose: 100-400 mcg/day, & may be given bid, or as once daily given in the morning or evening. Childn ≥7 yr Recommended dose: 200-800 mcg daily in 2-4 divided doses. Childn w/ mild to moderate asthma who have not previously received inhaled glucocorticosteroids, or who are already controlled on inhaled steroids (eg, budesonide or beclomethasone dipropionate) 200-400 mcg daily in 2 divided doses. May be increased up to 800 mcg during severe asthma. Childn 1-8 yr Bronchodilators alone: Initially 500 mcg/day once daily or bid in divided doses. Max: 500 mcg/day. Inhaled corticosteroids: 500 mcg/day or bid in divided doses. Max: 1,000 mcg/day. Oral corticosteroids: 1,000 mcg/day, administered either 500 mcg bid or 1,000 mcg once daily. Max: 1,000 mcg once daily. Symptomatic childn not responding to nonsteroidal therapy (eg, bronchodilator, mast-cell stabilizer) Initially 200 mcg once daily.

Hypersensitivity. Primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required.

Not for inj. Patients who are transferred from systematically active corticosteroids to inhaled corticosteroids (eg, budesonide); observing patients post-op or during periods of stress for evidence of inadequate renal adrenal response. Resume oral corticosteroids (in large doses) in patients who have been w/drawn from systemic corticosteroids during stress or severe asthma attack. Transfer from systemic corticosteroid therapy may unmask allergic conditions (eg, rhinitis, conjunctivitis, eczema). Compromised immune system. Not for rapid relief of bronchospasm, or other acute episodes of asthma. If paradoxical bronchospasm occurs, fast-acting inhaled bronchodilator must be given immediately; discontinue treatment & institute alternate therapy. Hypercorticism & adrenal suppression due to prolonged treatment w/ high doses. Rare instances of glaucoma, increased IOP & cataracts. Active or quiescent TB infection of resp tract, untreated systemic fungal, bacterial, viral or parasitic infections or ocular Herpes simplex. Possible growth suppression in childn during prolonged use. Monitor HPA axis function regularly if at risk of impaired adrenal function. Do not w/draw abruptly. Reduced liver function. Concomitant use w/ ketoconazole & itraconazole. Pregnancy & lactation. Childn.

Resp tract infection, rhinitis, coughing; otitis media, viral infection, moniliasis; gastroenteritis, vomiting, diarrhea, abdominal pain; ear infection; epistaxis, conjunctivitis; rash.

Increased mean plasma conc by ketoconazole. Increased systemic exposure w/ itraconazole, clarithromycin, erythromycin. Slight decrease in clearance & corresponding increase in bioavailability w/ cimetidine.

Antiasthmatic & COPD Preparations

R03BA02 - budesonide ; Belongs to the class of other inhalants used in the treatment of obstructive airway diseases, glucocorticoids.

D